Full Press Release Details
PellePharm Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome.
BBIO
PellePharm Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome
Key Takeaway: PellePharm Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis